AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada. Show more

Location: 150 West 4th Ave, Vancouver, BC, V5Y 1G6, Canada | Website: https://www.abcellera.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

1.192B

52 Wk Range

$1.89 - $5.82

Previous Close

$3.99

Open

$3.98

Volume

4,865,530

Day Range

$3.83 - $4.06

Enterprise Value

776.9M

Cash

553.1M

Avg Qtr Burn

-20.21M

Insider Ownership

22.94%

Institutional Own.

38.47%

Qtr Updated

06/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.